DOI: 10.12890/2024_004895
Secondary amyloidosis treated with tocilizumab as a complication of temporal arteritis
Authors
gtghinahaidar@gmail.com
Keywords
Temporal arteritis, amyloidosis, vasculitis, tocilizumab, chronic inflammationAbstract
Background: Temporal arteritis is a large-vessel vasculitis mostly seen in the elderly. Amyloidosis may be secondary to a chronic inflammation of body organs. Here, we present the second case report of temporal arteritis complicated by amyloidosis that was successfully treated by tocilizumab.
Case presentation: A 64-year-old female presented complaining of fatigue, fever, and diarrhea accompanied by abdominal pain. One year before presentation, she was diagnosed with temporal arteritis. She was treated with 15 mg/day oral prednisone for the last 6 months, with partial remission, but persistence of the fatigue and an elevated erythrocyte sedimentation rate (ESR, 56 mm/h). Physical examination showed tenderness of both temporal arteries and a soft abdomen. Colon tissue biopsy showed amyloid depositions in the vessels and stroma that were positive for Congo red staining. Tocilizumab was started with 8 mg/kg intravenous, the diarrhea resolved, and the arthralgia improved within 1 month, with a decrease in the ESR to 8 mm/h, and a C-reactive protein (CRP) level of 0.98 mg/dl. Monthly tocilizumab therapy remains efficacious 12 months later and was stopped due to lack of tocilizumab from the hospital. No side effects of tocilizumab were registered.
Conclusion: Chronic inflammation may be complicated by amyloidosis in patients with rheumatic diseases and genetic predisposition. Therefore, it is important to screen for intestinal Amyloid A (AA) amyloidosis in individuals with gastrointestinal disorders complicated by rheumatic disorders. AA amyloidosis may be complicated by temporal arteritis and presented with gastrointestinal symptoms such as diarrhea.
References
- Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol 2022;18:22-34.
- Yoshida S, Matsumoto H, Temmoku J, Shakespear N, Kiko Y, Kikuchi K, et al. Case report: Rapid development of amyloid A amyloidosis in temporal arteritis with SAA1.3 allele; An unusual case of intestinal amyloidosis secondary to temporal arteritis. Front Immunol 2023;14:1144397.
- Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am 2018;44:585-603.
- Altiparmak MR, Tabak F, Pamuk ON, Pamuk GE, Mert A, Aktuglu Y. Giant cell arteritis and secondary amyloidosis: the natural history. Scand J Rheumatol 2001;30:114-116.
- Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol 2022;74:1881-1889.
- Isomoto H, Kamo Y, Chen C, Nakao K. Clinical management of gastrointestinal amyloidosis. Open J Gastroenterol 2012;2:155-162.
- Okuda Y, Yamada T, Matsuura M, Takasugi K, Goto M. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid 2011;18:108-111.
- Jung JY, Kim YB, Kim JW, Suh CH, Kim HA. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Medicine (Baltimore) 2021;100:e26843.
- Almenara Tejederas M, Alonso García F, Aguilera Morales WA, de la Prada Álvarez F, Salgueira Lazo M. Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis. Nefrologia (Engl Ed) 2021:S0211-6995(21)00086-2.
- Hellmich B, Águeda AF, Monti S, Luqmani R. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep 2020;22:84.
